drugset / Trial / NCT05322499
Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
To observe and evaluate the efficacy and safety of camrelizumab combined with chemotherapy or anlotinib in patients with advanced esophageal squamous cell carcinoma previously Treated With First-line Immunotherapy
Timeline
- Start
- 2022-04-15
- Primary completion
- 2023-04-15
- Completion
- 2025-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Catequentinib | Small molecule | 12 mg | — |
| Subject | Docetaxel | Small molecule | 60 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 100 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 125 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 135 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | — |
| Subject | Paclitaxel-albumin | Unknown | 100 mg/m2 | — |
| Subject | Paclitaxel-albumin | Unknown | 135 mg/m2 | — |